Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse

This study has been terminated.

(The study ended prematurely due to the low accrual rate (24% of the expected accrual rate) in the first two years of patients enrolment)

Sponsor:

Information provided by (Responsible Party):

Hellenic Cooperative Oncology Group

ClinicalTrials.gov Identifier:

NCT00926107

First received: June 22, 2009

Last updated: November 9, 2011

Last verified: November 2011

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Study Completion Date:	October 2011
Primary Completion Date:	October 2011 (Final data collection date for primary outcome measure)